RxDoctor Payments Data

Andria Dotson

Family · Idaho Falls, IDNPI 1588365647

Payments from drug & device makers

$1,176in general payments, 2019–2025

Across 68 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$331
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$196
  • Otsuka America Pharmaceutical, Inc.$137
  • Axsome Therapeutics, Inc.$74
  • Vanda Pharmaceuticals Inc.$71
  • Teva Pharmaceuticals USA, Inc.$64
  • plus $302 from 10 others

What the payments were for

  • Food & beverage$1,176100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,176 in reported general payments places this provider in the 75th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$7,944
Medicare patients
18
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$94,914
SpravatoEsketamine Hcl30$53,616
CaplytaLumateperone Tosylate23$36,610
VraylarCariprazine Hcl28$32,300
TrintellixVortioxetine Hydrobromide14$6,723
BelsomraSuvorexant12$5,242
Atomoxetine Hcl12$2,927
Lamotrigine OdtLamotrigine11$2,373
Aripiprazole34$2,197
Venlafaxine Hcl ErVenlafaxine Hcl32$1,881
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine24$1,510
Prazosin Hcl44$1,267
Ondansetron OdtOndansetron14$1,159
Vilazodone Hcl19$1,137
Pregabalin11$749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$57$94,91413 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$196$36,61023 claims
AbbVieVraylar$331$32,30028 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$53$6,72314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 809 family providers in Idaho.

Other family in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →